Title of article
The Anticancer Natural Product Pironetin Selectively Targets Lys352 of α-Tubulin Original Research Article
Author/Authors
Takeo Usui، نويسنده , , Hiroyuki Watanabe، نويسنده , , Hiroshi Nakayama، نويسنده , , Yukio Tada، نويسنده , , Naoki Kanoh، نويسنده , , Masuo Kondoh، نويسنده , , Tetsuji Asao، نويسنده , , Koji Takio، نويسنده , , Hidenori Watanabe، نويسنده , , Kiyohiro Nishikawa، نويسنده , , Takeshi Kitahara، نويسنده , , Hiroyuki Osada، نويسنده ,
Issue Information
ماهنامه با شماره پیاپی سال 2004
Pages
8
From page
799
To page
806
Abstract
Pironetin is a potent inhibitor of tubulin assembly and arrests cell cycle progression in M phase. Analyses of its structure-activity relationships suggested that pironetin covalently binds tubulin. To determine the binding site of pironetin, we synthesized biotinylated pironetin, which inhibited tubulin assembly both in vitro and in situ. The biotinylated pironetin selectively and covalently bound with tubulin. Partial digestion of biotinylated pironetin-treated tubulin by several proteases revealed that the binding site is the C-terminal portion of α-tubulin. By systematic alanine scanning, the pironetin binding site was determined to be Lys352 of α-tubulin. Lys352 is located at the entrance of a small pocket of α-tubulin, and this pocket faces the β-tubulin of the next dimer. This is the first compound that covalently binds to the α subunit of tubulin and Lys352 of α-tubulin and inhibits the interaction of tubulin heterodimers.
Journal title
Chemistry and Biology
Serial Year
2004
Journal title
Chemistry and Biology
Record number
1158850
Link To Document